Literature DB >> 8306587

Prevalence of QT prolongation in a type 1 diabetic population and its association with autonomic neuropathy. The Neuropathy Study Group of the Italian Society for the Study of Diabetes.

R Sivieri1, M Veglio, A Chinaglia, P Scaglione, P Cavallo-Perin.   

Abstract

The prevalence of QT prolongation in a large random sample of Type 1 diabetic patients in Piemonte, Italy and its association with autonomic neuropathy were assessed. Three hundred and seventy-nine Type 1 diabetic patients (age 15-59) with (94, DAN+) and without (280, DAN-) autonomic neuropathy and 118 non-diabetic control subjects participated in the study. QT interval was measured on an ECG recorded at rest and QTc calculated according to Bazett's formula. QTc was greater than 0.440 s in 7.6% (95% CI 2.9-12.3) of control subjects, 25.6% (21.0-30.0) of diabetic patients, 30.8% (21.5-40.1) of DAN+, 23.9% (18.9-28.9) of DAN-. QTc was greater than 0.460 s (mean + 2SD of QTc in control subjects) in 11.7% (8.5-14.9) of diabetic patients, 18.1% (10.3-25.9) of DAN+, 9.6% (6.2-13.0) of DAN-. QT was above the 95% upper limit for the control subjects in the plot of measured QT against RR interval in 21.4% (17.3-25.5) of diabetic patients, 26.6% (17.7-35.5) of DAN+, 19.3% (14.7-23.9) of DAN-. No correlation was found between QT interval and age or disease duration. The prevalence of QT prolongation was higher in diabetic patients than in control subjects and in DAN+ than in DAN-.

Entities:  

Mesh:

Year:  1993        PMID: 8306587     DOI: 10.1111/j.1464-5491.1993.tb00007.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  21 in total

Review 1.  MIBG imaging.

Authors:  Amar D Patel; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2002 Jan-Feb       Impact factor: 5.952

2.  QTc interval, and autonomic and somatic nerve function in diabetic neuropathy.

Authors:  H Katsuoka; Y Mimori; K Kurokawa; T Harada; T Kohriyama; F Ishizaki; A Harada; S Nakamura
Journal:  Clin Auton Res       Date:  1998-06       Impact factor: 4.435

Review 3.  Cardiovascular autonomic neuropathies as complications of diabetes mellitus.

Authors:  Michael Kuehl; Martin J Stevens
Journal:  Nat Rev Endocrinol       Date:  2012-02-28       Impact factor: 43.330

Review 4.  Diabetes and cardiac autonomic neuropathy: Clinical manifestations, cardiovascular consequences, diagnosis and treatment.

Authors:  Akif Serhat Balcıoğlu; Haldun Müderrisoğlu
Journal:  World J Diabetes       Date:  2015-02-15

5.  Sudden cardiac death in diabetes mellitus: risk factors in the Rochester diabetic neuropathy study.

Authors:  G A Suarez; V M Clark; J E Norell; T E Kottke; M J Callahan; P C O'Brien; P A Low; P J Dyck
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-02       Impact factor: 10.154

6.  Use of corrected QT interval in autonomic function testing: assessment of reproducibility.

Authors:  M Veglio; S Maule; C Matteoda; R Quadri; M Valentini; O Pecchio; G Piancino; L Chiandussi
Journal:  Clin Auton Res       Date:  1996-12       Impact factor: 4.435

7.  Highly abnormal thermotests in familial dysautonomia suggest increased cardiac autonomic risk.

Authors:  M J Hilz; E H Kolodny; I Neuner; B Stemper; F B Axelrod
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-09       Impact factor: 10.154

8.  Scintigraphic evidence for cardiac sympathetic dysinnervation in long-term IDDM patients with and without ECG-based autonomic neuropathy.

Authors:  O Schnell; C M Kirsch; J Stemplinger; M Haslbeck; E Standl
Journal:  Diabetologia       Date:  1995-11       Impact factor: 10.122

9.  Effects of metoprolol on QT interval and QT dispersion in Type 1 diabetic patients with abnormal albuminuria.

Authors:  E Ebbehøj; H Arildsen; K W Hansen; C E Mogensen; H Mølgaard; P L Poulsen
Journal:  Diabetologia       Date:  2004-06-08       Impact factor: 10.122

Review 10.  QT interval, cardiovascular risk factors and risk of death in diabetes.

Authors:  M Veglio; A Chinaglia; P Cavallo-Perin
Journal:  J Endocrinol Invest       Date:  2004-02       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.